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Abstract
Background: The endometrial preparation with stimulating natural cycles for frozen
embryo transfer (FET) have benefits like lower cost and ease of use.
Objective: Comparing the clinical outcome of letrozole versus hormone replacement
(HR) for endometrial preparation in women with normal menstrual cycles for FET in
artificial reproduction techniques.
Materials andMethods:A total of 167 participants who had frozen embryos and regular
ovulatory cycles were randomly divided into two groups for endometrial preparation.
One group (82 women) was stimulated with letrozole 5mg/day and the other group
(85 women) was hormonally stimulated by oral estradiol valerate (2 mg three times a
day). All participants were followed serially by ultrasonography. Any patient who did
not reach optimal endometrial thickness was excluded from the study. Implantation,
biochemical and clinical pregnancy and abortion rate were reported.
Results: There was no significant difference in the mean age, duration, and primary or
secondary infertility, cause of the infertility, number, and quality of transferred embryos
between the groups. The mean estradiol level on the day of transfer was 643 ± 217 in
the HR group and 547 ± 212 in the letrozole group (P = 0.01), which was significantly
different. The clinical pregnancy rate was 38.7 in the letrozole group, higher than the
HR group (25.3) but not significantly different (P = 0.06).
Conclusion: For endometrial preparation in womenwith a normal cycle, letrozole yields
higher pregnancy rate although it is not significant; due to its cost, ease in use, and
lower side effects, letrozole is a good choice.
Key words: Letrozole, Hormone replacement, Endometrial, Preparation, Frozen,
Embryo.
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1. Introduction
Frozen-thawed embryo transfer (FET) in in-vitro
fertilization (IVF) cycles is a critical step to increase
the rate of pregnancy and to prevent ovarian hyper
stimulation syndrome (OHSS) (1).
Improved laboratory techniques by transferring
fewer embryos in the fresh transfer cycles have
led to an increase in the number of FET cycles (2).
One of the main principles in FET is endometrial
preparing for implantation of the thawed embryos
(3). Points affecting FET outcome include: embryo
quality, endometrium and embryo synchronization,
and the reception of endometrial (4). Although
increasing FET have significant effects on outcome,
there is no accepted best protocol in women with
ovulation for endometrial preparing (2).
There are different ways for endometrial
preparation1) Artificial cycle FET (AC-FET): In
this method, estrogen and progesterone are
administered in a sequential regimen to mimic
a normal endometrial cycle. At first, estradiol
is initiated to induce proliferative endometrium
and to suppress growing the dominant follicle.
Estrogen is prescribed till endometrial thickness
measured 7-9 mm on vaginal ultrasonography,
then progesterone is initiated for making secretory
phase (5). 2) Natural cycle (NC-FET): (A) The easiest
method for preparing endometrium is production
of steroids from a dominant follicle. Spontaneous
LH surge or administering HCG determine the
timing of embryo transfer (6). (B) Stimulated cycle
FET: In this cycle, ovulation is induced by drugs
such as clomiphene citrate, letrozole with or
without HMG. The endometrium is prepared
by endogenous estrogen and progesterone
(7).
Letrozole is an aromatase inhibitor which does
not decrease estrogen receptors. The normal
central feedback system is not affected by letrozole
and ovulation stays intact. It has no negative effect
on endometrium (8).
Letrozole cause increasing FSH by not allowing
estrogen making in granulosa cells from androgen.
Its half-life is ± 2 days while clomiphene citrate
half-life ± 2 wk; hence, antiestrogenic adverse
effects of letrozole does not affected endometrium
and cervix, and in comparison, to clomiphene
citrate letrozole might have more ovulation
induction properties like follicular growth and
endometrial development (9). Therefore, mono
ovulation with letrozole reduces the effect of
high estradiol on the endometrium and embryo
(10).
Considering the benefits, letrozole can be
an effective endometrial preparing drug for
FET cycles, its need more studies for clinical
efficacy. The purpose of this study was to compare
pregnancy outcome in stimulating with hormone
replacement and endometrial preparation in
patients with regular menstrual cycles with
letrozole who were routinely candidate for the
artificial cycle in our center.
2. Materials and Methods
2.1. Setting
This study was conducted as a randomized
clinical trial for a period of 12 months, commencing
on January 2018. Women who were referred to the
Infertility Center, Hazrate Zeinab Hospital, affiliated
to Shiraz University of Medical Sciences were
recruited in the study.
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The inclusion criteria were women aged 18-42 yr,
having frozen embryos, normal uterine cavity, nor-
mal endometrium without any endometrial polyp
or sub-mucosal myoma (according to normal hys-
terosalpingography, saline infusion sonography or
hysteroscopy), and BMI < 35 kg/m2. The exclusion
criteria were other maternal medical disease and
hydrosalpinx.
All participants meeting the inclusion criteria
were divided into two groups based on the
randomization table: the letrozole and hormone
replacement (HR) groups. The sample size was
calculated to be 74 cases in each group using the
following formula with α = 0.05 and power 80%.
Considering the probability of dropout, the study
included 167 women, 82 in the letrozole group
and 87 in the HR group. Two women from each
group did not reach proper endometrial thickness
and discontinued the intervention. Vaginal ultra-
sonography was done on the second day of the
menstrual cycle for the evaluation of ovaries and
endometrium.
2.2. Endometrial preparation, embryo
transfer, and luteal phase support
2.2.1. Letrozole group
Participants were prescribed 5 mg letrozole/day
from the third day to the seventh day of the men-
strual cycle. Follicular development was monitored
by vaginal ultrasonography starting on the 10th day
of the menstrual cycle; if the follicular diameter was
≥ 17 mm and the endometrial thickness reached
7-9 mm, they were given 10,000 unit of HCG,
and 36-48 hr after that, they were progesterone
ampule 100 mg was given intramuscularly/day for
three to five days depending on the embryo’s
age. Then, the embryos were transferred and
progesterone 100mg/IM per day was continued for
three days after the transfer and then changed to
progesterone suppository 400 mg Q12 hr (rectal or
vaginal) 14-16 days after the transfer.
If on the 10th day of the cycle, the dominant
follicle was ≥ 14 mm to < 17 mm, a serial vaginal
ultrasonography (every other day) was repeated
without adding any medication until the follicle
reached 17 mm or more or the endometrial thick-
nesswas 7-9mm. After that, HCGwas administered
and like the first method progress was continued.
However, if on the 10th day, the dominant follicle
size was < 14 mm, HMGwas injected daily for three
to four days until the follicular diameter was > 17mm
or the endometrial thickness was 7-9 mm, and then
HCG was injected. If by the 17th day of the cycle,
the dominant follicle did not reach 17 mm or if the
endometrial thickness was < 7 mm, the cycle was
canceled.
2.2.2. HRT group
The participants were prescribed oral estradiol
valerate (2 mg three times a day) starting on
the second to the third day of menstrual cycle,
and on the 10th day, the endometrial thickness
was monitored by vaginal ultrasonography. If the
endometrial thickness was 7-9 mm and three-line
pattern, estrogen was continued and progesterone
therapy was initiated 100mg IM/day for three to five
days depending on the embryo’s age. Then, it was
continued after the embryo transfer for three days
and then changed to progesterone suppository
400 mg Q 12 hr.
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If endometrial thickness was < 7 mm on the
10th day of the estradiol consumption, the estra-
diol dosage was increased to 8 mg/day and
endometriumwas evaluated by vaginal ultrasonog-
raphy three to four days later. If the endometrial
thickness was inappropriate, the cycle was can-
celed.
2.3. Pregnancy diagnosis
HCG level was measured 14 days after the
embryo transfer and if it was > 25 IU/L, it was
defined as a biochemical pregnancy. Ultrasonog-
raphy was performed 28-30 days after the embryo
transfer, having a fetal heart beat was defined as
a clinical pregnancy. For pregnant women in the
letrozole group, progesterone suppository 400 mg
twice daily was continued till 12 wk of gestational
age. In the HR group, oral estradiol continued till
8 wk and suppository progesterone 400 mg twice
daily was continued till 12 wk of gestational age.
2.4. Ethical consideration
A written informed consent was obtained
from all participants. The study protocol has
been approved by the ethics committee of
the Shiraz University of Medical Sciences
(IR.SUMS.REC.1397.406).
2.5. Statistical analysis
Date were analyzed using the Statistical Pack-
age for the Social Sciences, version 22, SPSS Inc,
Chicago, Illinois, USA. The mean was compared
using one-way analysis of variance (ANOVA) and
two-sample t-tests. The proportion for the two
groups was compared using the x2-test, p < 0.05
was considered to be statistically significant.
3. Results
This was a prospective trial comparing the
outcome of endometrial preparation in frozen
embryos transfer cycle by letrozole and hormone
replacement. In the letrozole group, 82 women
were followed, the analysis was limited to 80
women, since 2 of them (2.5%) were excluded due
to non-development of the dominant follicle and
endometrial growth (Figure I). Poor endometrial
development had occurred in 2 out of 85 (2.3%)
patients in the second group (HR). As shown in
Table I, the two groups had no significant difference
in age, BMI, time and type of infertility (primary or
secondary), serum FSH, and AMH.
The cause of infertility (male factor, PCOS, unex-
plained, hypo-gonadotropic hypogonadism, tubal
factor) with p = 0.22 has no significant difference.
Table II shows no significant difference between
the stimulation duration, dose of gonadotropins,
number of MII oocyte, and number of embryos.
As shown in Table III, there was no significant
difference between the two groups pertaining to
the duration of endometrial proliferation phase
(day), the number of transferred embryo/cycles, the
date of the embryo (cleavage or blastocyst), and
the endometrial thickness at the end of follicular
phase (mm).
The clinical pregnancy rate was higher in the
letrozole group (38.7%) than in the artificial group
(25.3%) but not significant. Furthermore, the first
trimester abortion rate was non-significantly lower
in the letrozole group (Table IV).
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In this study, 20 patients who participated in
the HR group and failed to reach pregnancy were
scheduled to use letrozole in the next menstrual
cycle, and of them, 35% became pregnant (7/ 20),
but three had an early abortion (45% of clinical
pregnancy).
Table I. Demographic and hormonal data of study groups
HR group (n = 83) Letrozole group (n = 80) P-value
Age 32.25 ± 4.6 33.28 ± 4.48 0.17*
BMI 26.5 ± 6.6 27.8 ± 8 0.72*
FSH 5.9 ± 2.3 5.9 ± 1.7 1*
AMH 2.8 ± 2.8 3 ± 2.09 0.69*
Time of infertility 7.5 ± 4.9 7.09 ± 4.1 0.51*
Primary/secondary infertility (yr) 54/29 61/19 0.11**
Data are presented as Mean ± SD, *Analysis was performed using the t-test and **Chi-square test
HR: Hormone replacement; BMI: Body mass index; FSH: Follicle-stimulating hormone; AMH: Anti-Müllerian hormone
Table II. Comparison of stimulation data and oocytes and embryos quality
HR group (n = 83) Letrozole group (n = 80) P-value
Stimulation days 10.3 ± 2.4 11 ± 2.3 0.27
Human menopausal gonadotropin dose
(IU)
2491 ± 795 2604 ± 901 0.87
No. of oocytes in metaphase II
maturation stage (MII)
9.03 ± 5.79 9.07 ± 4.17 0.95
Number of embryos 4.58 ± 2.5 5.1 ± 2.2 0.16
Data are presented as Mean ± SD, Analysis was performed with the t-test.
HR: Hormone replacement; IU: International unit, The quality of embryos in both groups had no significant differences (p = 0.72)
Table III. Embryo transfer cycles data between case and control groups
HR group (n = 83) Letrozole group (n = 80) P-value
Proliferation days 10.89 ± 1.95 10.83 ± 1.43 0.83
Endometrial thickness 8.26 ± 0.47 8.20 ± 0.58 0.44
Estradiol on the day of transfer 643 ± 217 547 ± 212 0.01
Number of embryo/cycles 2.48 ± 0.77 2.41 ± 0.66 0.58
Data are presented as Mean ± SD, Analysis was performed with the t-test, HR: Hormone replacement
Table IV. Pregnancy outcome in letrozole and HR groups
HR group (n = 83) Letrozole group (n = 80) P-value
Chemical pregnancy 28.9% 40% 0.13
Clinical pregnancy 25.3% 38.7% 0.06
Abortion 6% 7.6% 0.7
Data are presented as percentages; analysis was performed using the Chi-square test, HR: Hormone replacement
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Assessed for eligibility (n = 176)
Excluded (n = 9) 
• Not meeting inclusion criteria (n = 0) 
• Declined to participate (n = 9) 
Lost to follow-up (no proper endometrial 
thickness) (n = 2) 
Allocated to intervention (n = 82) 
Received allocated intervention (n = 82) 
Lost to follow-up (no proper endometrial 
thickness) (n = 2) 
Allocated to intervention (n = 85) 





Randomized (n = 167) 
Analysed (n = 83) 
Excluded from analysis (give reasons) (n = 0) 
Analysed (n = 80) 
Excluded from analysis (give reasons) (n = 0) 
Figure 1. Consort diagram.
4. Discussion
In this study we detected that the clinical and
chemical pregnancy ratewas higher in the letrozole
group although it was not significant. The study
reported a significant lower level of estradiol in
the letrozole group. We compared endometrial
preparation for FET cycles with artificial hormone
replacement versus mild ovarian stimulation with
letrozole which did not have any significant differ-
ence in endometrial thickness between the two
groups.
Studies reported that ovarian stimulation by
aromatase inhibitors is because lower levels of
estrogen production per follicle had overall lower
estrogen level. Adding letrozole to gonadotropin
for ovarian stimulation reduced the gonadotropin
dosage and decreased the peak estradiol level
(9). Sibai and colleagues study reported the mean
endometrial thickness in the letrozole group was
significantly lower (9.9 mm vs 9.1 mm), the clinical
pregnancy rate in the letrozole group was signifi-
cantly higher, but the chemical pregnancy rate had
no significant differences like this study (3).
Developing corpus luteum and better endome-
trial receptivity led to higher pregnancy rate in the
letrozole group. However, in the HR cycle, estrogen
and progesterone does not suppress completely
the pituitary gland and dominant follicle. If this
follicle leads to spontaneous luteinization, the
endometrium might have been exposed to proges-
terone earlier, which increases the risk of incorrect
timing of the transfer, implantation, and pregnancy
rate (11).
In Huang’s study, the live birth rate was 38.89%
and the clinical pregnancy rate was 47% in the
letrozole FET cycle (12).
Letrozole rapidly absorbs and reaches maximum
blood concentration 1 hr after its oral administration
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and also high bioavailability and a short half-life
(45 hr), resulting in complete removal of the drug
during the implantation period. The administration
of letrozole at a low dose induces single follicular
development and it has a high rate of ovulation;
hence, preparing the endometrium for FET.
When considering the advantages of endome-
trial preparation methods, pregnancy outcome is
not the only important issue, but one has to
consider its convenience, cost, and lower risk of
venous thromboembolic events in obese and high-
risk patients.
Artificial hormonal cycles might still be the first
choice for women in FET cycles, but this protocol
cause cost and discomfort. It requires administra-
tion of high estrogen and progesterone doses for
luteal phase support in the first trimester. So, in
patients with normal menstrual cycles, it is better
to find other choices.
There has been no protocol for endometrial
preparing by letrozole.
5. Conclusion
For endometrial preparation in women with a
normal cycle, letrozole yields higher pregnancy
rate although it is not that significant; due to its
benefit, lower side effects, and the patient’s comfort
in the use of medication, letrozole is a better choice
for endometrial preparation.
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